Toluene sulfonamide injection (PTS), a new anticancer drug of HongRi pharmaceutical, has entered the green channel

On August 19, sun Changhai, general manager of HongRi Pharmaceutical Co., Ltd (300026 SZ), said in the investigation of the institution that the company's first class new anti-cancer drug, toluene sulfonamide injection (PTS), has entered the green channel of drug review, but it is affected by the recent reports of CFDA by real name, "or can enter the review stage in April and may next year", and will follow up the direction of obtaining the production approval next year Recently, the CFDA has been in constant turmoil Officials of Hunan Commission for Discipline Inspection reported to the former director of the Drug Administration for the classification of honeysuckle and honeysuckle On August 18, representatives of the National People's Congress, Ma Wenfang, a village doctor in Henan Province, and Zhang Yi, chairman of Henan Yisheng Pharmaceutical Co., Ltd reported to relevant officials in real name In fact, in May this year, CFDA has accepted the application of red sun pharmaceutical PTS for production application, and entered the special review process At present, PTS has not yet passed the expert meeting, and the review speed is slower than expected As a new anticancer drug, PTS has been proved to be effective in the treatment of breast cancer, skin cancer, nasopharyngeal cancer and bronchogenic cancer in phase I clinical trials According to Guotai Junan Research Report, PTS has a broad application prospect in the field of tumor diagnosis and tumor assisted resection, and it is expected to reach the magnitude of 1 billion yuan rapidly after being listed on the market The drug was developed by Tianjin hongrijiandakang, a joint-stock company of HongRi pharmaceutical industry, led by Zhong Nanshan and other three academicians At present, HongRi pharmaceutical holds 12.5% of the equity of the joint-stock company.